Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Citi
US Department of Justice
Daiichi Sankyo
Cipla
UBS

Generated: July 17, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,574,622

Try a free trialSee Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,574,622 protect, and when does it expire?

Patent 8,574,622 protects NATESTO and is included in one NDA.

This patent has twenty-seven patent family members in twenty-one countries.

Summary for Patent: 8,574,622
Title:Controlled release delivery system for nasal applications
Abstract: This invention relates to a pernasally administrable preparation for the controlled release of sexual hormones to the systemic circulation, in particular to a formulation which enables its active ingredient to be absorbed in a sustained manner providing a better bioavailability at very low doses and longer duration of action.
Inventor(s): Mattern; Claudia (Stans, CH)
Assignee: M & P Patent Aktiengesellschaft (Vaduz, LI)
Application Number:13/194,928
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 8,574,622
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Compound;

Drugs Protected by US Patent 8,574,622

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Aytu NATESTO testosterone GEL, METERED;NASAL 205488-001 May 28, 2014 RX No No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,574,622

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
03025769Nov 11, 2003

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Accenture
McKinsey
Harvard Business School
UBS
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.